Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
13 May 2025AmrProfiler: a comprehensive tool for identifying antimicrobial resistance genes and mutations across species
AmrProfiler is a tool that identifies antimicrobial resistance (AMR) genes, resistance-associated mutations, and ribosomal RNA gene mutations across nearly 18,000 bacterial species. It integrates data from established databases and is the first to report mutations in rRNA genes. AmrProfiler supports genome assemblies in multiple formats and allows users to customize detection thresholds. It provides actionable […]
Read more... -
09 May 2025Efforts to develop therapeutic agents for bacterial infections to fight against AMR
Antimicrobial resistance (AMR) poses a global threat, but few new antimicrobials are in development. The G7 has been focusing on AMR since 2015, and the 2023 G7 Hiroshima Leaders’ Communiqué aims to explore push and pull incentives. The World Health Assembly adopted the Global Action Plan on AMR in 2015, and Japan developed its first […]
Read more... -
05 May 2025An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens
Antibiotic resistance is a global health crisis, especially for Gram-negative bacteria infections. NM102, a molecule, exhibits antimicrobial activity in infection contexts. It inhibits the Mutation Frequency Decline protein, sensitizing pathogenic bacteria to the host immune response and blocking infections. This could lead to the development of drugs to combat antimicrobial resistance.
Read more...
More news related to Smart innovation
